You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

934 Results
Document
Jun 2021
Document
Jun 2021
Document
Jun 2021
Document
Jul 2021
Document
Jul 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021

Pages